Medochemie Ltd. Ramps Up Investment In Central Europe; Data3s Awarded Major IT Contract

Online, April 18, 2013 (Newswire.com) - Data3s today announced it has been selected to provide a major overhaul of Medochemie's data infrastructure that will unify the company's information systems and enable better sharing of information among countries.

This major systems integration project will complement the modernization work already underway at Medochemie Ltd. to realize their vision of becoming the most technologically advanced international generics pharmaceutical company in Europe. While financial details have not been released, sources in Medochemie indicate that this is the largest infrastructure investment of its kind in over a decade.

The project will focus on improving key aspects of Medochemie's operations, including faster turnaround of exports in response to local demands, improved quality of service, shorter payment terms for suppliers and partners, as well as improved visibility in key markets. Chief among Medochemie's goals is the improvement of its existing business, as well as the company's ability to identify and capitalize upon previously unexploited business opportunities.

The first phase of Medochemie's modernization program will focus on the Central-Southern European zone, and will include major investments in their operations in the Czech Republic, Slovakia and Bulgaria, in addition to the company's seat in Cyprus.

"The countries we have selected for this 'pilot' are representative of our European affiliates," said Alexis Neophytou, Medochemie's CEE Zone Director. "We want to measure the impact of our investment here first - first to make sure we are measuring the right key performance indicators in place, and second, to establish a set of standards that we can apply elsewhere," Mr. Neophytou added.

According to Yiannakis Mouzouris, the company's Export Manager, Medochemie's position as an "enormously successful export company" has largely protected it from the current financial crisis. "Over 97% of our revenues are generated abroad," Mr. Mouzouris said, "much of that in Central and Eastern Europe. To maintain our integrity and grow in these markets, we are committing significant financial resources to build and support our operations there. Improvement of IT operations is naturally a part of this," Mr. Mouzouris added.

Mr. Mouzouris also noted that Medochemie Ltd. will also direct investment to their distribution network, shoring up loyalty and support among sales and distribution partners in key markets, while expanding their reach through new sales channels. "We are committed to our partners as well as our customers," Mr. Mouzouris said, "and with better, faster and more responsive technology at our fingertips, we will have the insight to bring more value to them more quickly."

About Medochemie Ltd.

Medochemie Ltd is an international generic pharmaceutical manufacturer headquartered in Cyprus and a member of EGA (European Generic Medicines Association). Medochemie manufactures a wide range of oral solid dosage forms, oral solutions, powder and solutions for injection, dry powders for inhalation, and creams, ointments and suppositories. With a worldwide marketing operation, Medochemie aims to provide every human being around the globe with quality and affordable drug treatment. To learn more about Medochemie, please visit www.medochemie.com.

About Data3s

Data3s is one of the fastest growing providers of innovative solutions for customer relationship management (CRM), business intelligence, multi-channel marketing, eLearning, clinical studies, and creative business solutions for life science organizations worldwide. Our high quality products employ the latest technologies to help our customers sell more, faster and achieve better results. Founded in 2006, Data3s is a privately owned company headquartered in Prague, Czech Republic, with full-service partners and representative offices across Europe and Asia. To learn more about Data3s, please visit www.data3s.com